MarginsXMarginsX
Home › Markets › CLDWW

Calidi Biotherapeutics, Inc. (CLDWW)

CLDWW is quoted over the counter, not listed on an exchange. Calidi Biotherapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close
No daily closes stored yet
No new price since Oct 15, 2025: the price source has sent no bar for 138 sessions
1-year return
No daily closes stored yet
Market cap
The company also trades on NYSE as CLDI; this OTC line is another class or a foreign line, so its cap is not computed
P/E and P/S
Needs a market cap · Needs a market cap
On trailing twelve months to June 30, 2026 (10-Q)

Profile

FieldValue
TickerCLDWW, quoted over the counter
SEC CIK0001855485
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codeBiological Products, (No Diagnostic Substances)
Business addressSan Diego, CA
Incorporated inDE

Warning signs

Cash runway
2.9 months
$4.3M cash at June 30, 2026
Share count, 1 year
+669.9%
2025-11-10 to 2026-11-11 · +18588.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
-$1K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements."
10-Q 2026-11-13
Cash and burn$4.3M cash; operating cash flow -$4.4M a quarter.Report 2026-06-30
Shares outstanding3,449,184 (2026-11-11); 7,167,721 a year earlier; 35,436,381 three years earlier. 1y figure adjusted for splits (1-for-16 overall); 3y figure adjusted for splits (1-for-1920 overall).Cover page 2026-11-11
Reverse splits, 3 years3; latest 1-for-16 on 2026-07-31Source 2026-07-31
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-09-17
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-09-25
AuditorCBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-05-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$4.2M-$4.4M$4.3M$600KNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$4.1M-$4.1M$6.8M$600KNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed-$4.1M-$5.0M$5.8M$600KNeeds four quarters10-K 2026-03-27
Q3 2025
2025-09-30
Not filed-$5.1M-$4.2M$10.6M$600KNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
Not filed-$5.7M-$4.9M$5.4M$600KNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$5.0M-$7.1M$10.8M$600KNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$4.1M-$5.4M$9.6M$600KNeeds four quarters10-K 2026-03-27
Q3 2024
2024-09-30
Not filed-$5.1M-$4.9M$1.9M$2.4MNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-17
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-06-05

Source: SEC EDGAR submissions feed, 408 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier